Table 1

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Case | Age (yr) | Sex | Weight (kg) | Underlying disease | Fungal disease^ | Localisation of fungal infection | Species cultured | Initial dose before TDM | No. of samples | Concentration range (mg/L) | Inter-vention | Adequate troughs before inter-vention | Adequate troughs after inter-vention | Adverse events | Response# |
| 3 | 0 | F | 6.7 | ALL infant leukemia | none¤ | lungs | none | 4 mg/kg BID IV | 2 | 0.09-0.22 | no | 0/2 | - | none | complete |
| 13 | 0 | M | 5.1 | Hemo-phagocytic lymphohistiocytosis, relapse | none¤ | lungs | none | 35 mg BID PO | 2 | <0.1 | no | 0/2 | - | nephro- and hepatotoxicity | complete |
| 1 | 2 | F | 14 | ALL | proven | CNS and lungs | *A. fumigatus* | 160 mg BID PO | 4 | 0.89-3.34 | yes | 0/2 | 2/2 | exanthema and hepatotoxicity | complete |
| 17 | 2 | M | 15 | Juvenile myelomonocytic leukemia | none¤ | unknown | none | 200 mg BID PO | 2 | 1.77-5.6 | no | 2/2 | - | none | complete |
| 7 | 3 | F | 14.6 | ALL | possible | lungs | none | 7 mg/kg BID IV | 1 | 6 | no | 1/1 | - | none | partial |
| 8 | 3 | M | 15.4 | Down syndrome, hemo-phagocytic lymphohistiocytosis, relapse, allo-SCT | none¤ | unknown | none | 7 mg/kg BID IV | 1 | 0.97 | no | 1/1 | - | none | death |
| 14 | 3 | F | 17.8 | ALL | proven | candidemia | *C. albicans* | 80 mg BID PO | 1 | 3.6 | no | 1/1 | - | none | progression |
| 11 | 5 | F | 18.5 | Oculocutaneous albinism, medulloblastoma | probable | lungs | none\* | 8 mg/kg BID IV | 1 | 1.25 | no | 1/1 | - | hepatotoxicity | complete |
| 6 | 7 | M | 32.6 | ALL | proven | CNS and lungs | *A. fumigatus* | 200 mg BID PO | 4 | <0.1-5.89 | yes | 0/2 | 2/2 | phototoxicity of skin | stable |
| 9 | 7 | F | 25.3 | ALL | proven$ | lungs and liver | none | 200 mg BID PO | 3 | <0.1-1.21 | no | 0/3 | - | none | partial |
| 12 | 8 | F | 19.2 | Non-Hodgkin lymphoma | probable | lungs | *A. fumigatus* | 200 mg BID PO | 3 | 0.21-2.83 | yes | 0/1 | 2/2 | phototoxicity of skin | complete |
| 4 | 11 | M | 30 | CML, relapse, allo-SCT | possible | lungs | none | 150 mg BID PO | 1 | 3.1 | no | 1/1 | - | none | stable |
| 15 | 14 | F | 53 | ALL |  none¤ | unknown | none | 200 mg BID PO | 1 | 9.6 | no | 1/1 | - | none | complete |
| 2 | 15 | M | 52 | CF | not applicable | ABPA% | none | 160 mg PO (morning), 200 mg PO (evening) | 1 | 1.2 | no | 1/1 | - | exanthema  | not applicable |
| 16 | 15 | F | 50 | ALL, relapse | proven | candidemia | *C. tropicalis* | 200 mg BID PO | 1 | 4.54 | no | 1/1 | - | none | progression |
| 10 | 16 | M | 63.1 | ALL | possible | lungs and possibly abdomen | none | 3 mg/kg BID IV | 1 | 5.7 | no | 1/1 | - | none | unknown |
| 18 | 16 | F | 46.8 | Abdominal Burkitt-lymphoma | probable | lungs | none\* | 200 mg BID PO | 3 | 0.7-1.81 | yes | 0/1 | 1/2 | none | complete |
| 5 | 18 | M | 66 | AML, relapse, allo-SCT | possible | CNS | none | 3 mg/kg BID IV | 7 | <0.1-3.22 | yes | 0/2 | 3/5 | none | partial |

^Classification according to the revised EORTC-MSG 2008 criteria (3)

#Response to treatment until nine weeks after initiation according to the EORTC-MSG 2008 criteria (9), based on available radiologic imaging (X-thorax or (HR)CT-scan)

%Allergic Broncho-Pulmonary Aspergillosis

¤Persistent febrile neutropenia

$Culturing of fungi unsuccessful, but fungal structures were seen in histology from liver biopsy

\*Galactomannan-testing positive